Adel Samson
MD PhD
Oncologist
👥Biography 个人简介
Adel Samson at Leeds contributed to clinical development of CAVATAK (coxsackievirus A21) — an oncolytic virus that targets ICAM-1-expressing melanoma cells — including the CALM and MITCI trials demonstrating clinical activity as monotherapy and in combination with ipilimumab in advanced melanoma. His work contributed to establishing coxsackievirus as a clinically active oncolytic agent.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Adel Samson 的研究动态
Follow Adel Samson's research updates
留下邮箱，当我们发布与 Adel Samson（University of Leeds）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment